infants at highest risk of RSV

Efficacy and Safety

SYNAGIS®: Proven protection against 
severe RSV disease for more than 25 years1

SYNAGIS significantly reduced RSV hospitalizations and the severity of those hospitalizations in the highest-risk populations1-4

Infants at higest risk RSV

Pivotal trial icon

Two pivotal trials included nearly 
2800 of the most vulnerable patients1-3:

IMpact-RSV TRIAL Preterm infants with and without BPD FELTES TRIAL Children with HS-CHD 

IMpact-RSV PIVOTAL TRIAL

SYNAGIS: PROVEN TO PROTECT PRETERM INFANTS WITH AND WITHOUT BPD1,2

Preterm infants Icon and lung Icon

Primary analysis

SYNAGIS significantly reduced RSV hospitalizations by 

55

in preterm infants with 
and without BPD1,2 

(RSVH rate 10.6% with placebo vs 4.8% 
with SYNAGIS; P<0.001)
 

Flip image Icon
X

Primary analysis: 

Preterm infants with and without BPD2

Reduced Hospitalizations in premature  infants with and without BPD Graph
 

Study Design

1502 patients were randomized in the IMpact-RSV trial.2

740 preterm infants 
≤35 wGA without BPD  

  • 405 very preterm infants <32 wGA  
  • 335 preterm infants 32-35 wGA

762 children 
≤24 months of age 
with BPD

A multicenter, randomized, placebo-controlled trial in infants born at ≤35 wGA and ≤6 months of age or children with BPD ≤24 months of age randomized 2:1 to receive 1 injection of palivizumab (15 mg/kg) (n=1002) or an equal volume of placebo (n=500) every 30 days for a total of 5 doses.2
 

Primary group analysis

SYNAGIS showed a significant reduction in RSV hospitalizations in each of the primary inclusion groups1,2*

Reduction Arrows Icon

78%

reduction in RSVH in preterm infants ≤35 wGA

(RSVH rate 8.1% with placebo vs 1.8% with SYNAGIS; P<0.001)


39%

reduction in RSVH in children with BPD <24 months of age

(RSVH rate 12.8% with placebo vs 7.9% with SYNAGIS; P=0.038)

*The prespecified primary inclusion populations in the IMpact-RSV trial were preterm infants ≤35 wGA and ≤6 months of age and children with BPD ≤24 months of age.2

Subgroup analysis

SYNAGIS reduced RSV hospitalizations by 

72%

among very preterm infants4† 

 

(RSVH rate 6.5% with placebo vs 1.8% 
with SYNAGIS)

Flip image Icon
X

Subgroup analysis:

Very preterm infants <32 wGA without BPD4

 Reduced Hospitalizations among very preterm infants without BPD Graph

Secondary Endpoints

SYNAGIS significantly reduced RSVH severity in preterm infants with and without BPD.2‡

Calendar Icon

42%

fewer days of RSV hospitalization

(per 100 children: 62.6 days with placebo vs 36.4 days with SYNAGIS; P<0.001)

Chart Icon

57%

lower rate of ICU admissions

(3.0% with placebo vs 1.3% with SYNAGIS; P=0.026)

Supplemental Oxygen Icon

40%

fewer days with increased supplemental oxygen

(per 100 children: 50.6 days with placebo vs 30.3 days with SYNAGIS; P<0.001)

Subgroup analyses should be interpreted with caution due to their inherent limitations and results from these analyses may differ from those observed in clinical practice. 

The placebo and SYNAGIS groups did not show significant differences in incidence of mechanical ventilation (0.2% vs 0.7%, P=0.280) or total days of mechanical ventilation (1.7 days vs 8.4 days, P=0.210). ICU total days were 12.7 with placebo and 13.3 with SYNAGIS (P=0.023).2
 

Most frequently reported adverse events 
that were judged to be potentially related to study drug

 

Placebo (n=500)

SYNAGIS (n=1002)

Fever

3.0%

2.8%

Nervousness

2.6%

2.5%

Injection-site reaction

1.6%

2.3%

Diarrhea

0.4%

1.0%

§Reported events in at least 1% of children in the palivizumab group are provided along with the corresponding incidence in the placebo group. These represent adverse events reported by the investigator and include those identified by protocol-mandated testing and other clinically indicated evaluations.2

FELTES PIVOTAL TRIAL

SYNAGIS: PROVEN TO PROTECT CHILDREN WITH HS-CHD1,3

heart Icon

Primary endpoint analysis

SYNAGIS significantly reduced RSV hospitalizations by

45%

among children ≤24 months of age with HS-CHD1,3

(RSVH rate 9.7% with placebo vs 5.3% 
with SYNAGIS; P=0.003)

Flip image Icon
X

Primary endpoint analysis:

Children ≤24 months of age with HS-CHD3

 Reduced Hospitalizations among HS-CHD patients Graph
 

Study Design

1287 children with HS-CHD were randomized in the Feltes trial.3

A randomized, double-blind, placebo-controlled trial of 1287 children ≤24 months of age with hemodynamically significant CHD randomly assigned 1:1 to receive 5 monthly intramuscular injections of SYNAGIS 15 mg/kg or placebo. The study was conducted during 4 consecutive RSV seasons at 76 centers in the United States (n=47), Canada (n=6), Sweden (n=3), Germany (n=4), Poland (n=6), France (n=4), and the United Kingdom (n=6). Each child participated during only one RSV season. Results may not be generalizable to a US population.3
 

Secondary Endpoints

SYNAGIS significantly reduced RSVH severity in children with HS-CHD.3II

Calendar Icon

56%

fewer total days of RSV-related hospitalizations

(per 100 children: 129 days with placebo vs 57.4 days with SYNAGIS; P<0.003)

Supplemental Oxygen Icon

57%

fewer total days with increased supplemental oxygen

(per 100 children: 101.5 days for placebo vs 27.9 days with SYNAGIS; P<0.014)

IIThe placebo and SYNAGIS groups did not show statistically significant differences in incidence of RSV-related ICU admissions (3.7% vs 2.0%, P=0.094), total days of RSV-related ICU stays per 100 children (71.2 days vs 15.9 days, P=0.80), incidence of RSV-related mechanical ventilation (2.2% vs 1.3%, P=0.282), or total days of RSV-related mechanical ventilation per 100 children (54.7 days vs 6.5 days, P=0.224).3

Most frequently reported adverse events 
that were judged to be potentially related to study drug

 

Placebo (n=648)

SYNAGIS (n=639)

Fever

23.9%

27.1%

Infection

2.9%

5.6%

Injection-site reaction

2.2%

3.4%

Upper respiratory infection

46.1%

47.4%

Conjunctivitis

9.3%

11.3%

Arrythmia#

1.7%

3.1%

Cyanosis#

6.9%

9.1%

Few adverse events were reported at an absolute incidence >1% higher in the SYNAGIS group compared with the placebo group.3

#None of these events reported as arrhythmia and one reported as cyanosis (placebo recipient) were judged related to the study drug.3

BPD=bronchopulmonary dysplasia; CHD=congenital heart disease; HS-CHD=hemodynamically significant congenital heart disease; ICU=intensive care unit; RSV=respiratory syncytial virus; RSVH=respiratory syncytial virus hospitalization; wGA=weeks gestational age. 

REFERENCES: 1. SYNAGIS (palivizumab) [prescribing information]. Waltham, MA: Sobi, Inc. 2021. 2. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531-537. 3. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532-540. 4. Data on file. Sobi, Inc. 

All imagery is for illustrative purposes only.
 

ALL INFANTS ARE NOT THE SAME

INDICATION

SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

  • with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
  • with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
  • with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions: Anaphylaxis and anaphylactic shock (including fatal cases) and other severe acute hypersensitivity reactions have been reported. Permanently discontinue SYNAGIS and administer appropriate medication if such reactions occur.

Coagulation Disorders: SYNAGIS should be given with caution to children with thrombocytopenia or any coagulation disorder.

RSV Diagnostic Test Interference: Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.

Serious Adverse Reactions: The most common serious adverse reactions occurring with SYNAGIS are anaphylaxis and other acute hypersensitivity reactions.

Most Common Adverse Reactions: The most common adverse reactions are fever and rash.

Postmarketing Experience: Severe thrombocytopenia and injection site reactions have been identified during post approval use of SYNAGIS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

LIMITATIONS OF USE

The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.

CONTRAINDICATIONS

Previous significant hypersensitivity reaction to SYNAGIS.

INDICATION

SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

  • with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
  • with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
  • with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

 

These are not all the possible risks associated with SYNAGIS. Please see full Prescribing Information for SYNAGIS, including Patient Information. To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or the FDA at 1-800-FDA-1088.

For Colorado prescribers, visit synagishcp.com/wac-pricing.